The life sciences industry has spent decades digitizing, and despite significant investment in LIMS, ELN, MES, and scheduling tools, most pharma, biotech, and CDMO organizations operate across fragmented systems that trap data in silos, force costly manual handoffs, and leave scientific talent spending up to 90% of their time on data preparation rather than science. AI won’t fix that. In fact, it makes the problem more visible: without a governed, contextualized data foundation, agentic AI stalls at the pilot stage.
In this white paper, Vasu Rangadass, Ph.D., President and CEO of L7 Informatics, makes the case for what he calls the Agentic Pivot: a strategic reorientation away from the “tools-first” procurement model that has defined the industry’s modernization journey, and toward a unified operating model where AI can reason, plan, act, and reflect within a compliant, data-rich environment. Drawing on research from MIT Sloan Management Review and Boston Consulting Group, the paper examines the true cost of fragmentation, the emerging tool-coworker duality of agentic AI, and the ROI case for unified orchestration across the molecule-to-market lifecycle.
What’s inside goes beyond strategy. The paper details the architectural requirements for an agentic operating system purpose-built for regulated science, including ontology-driven data contextualization, GxP-native compliance, and retrieval-first AI grounding, and maps a practical roadmap for leaders ready to move from AI-ready foundations to AI-actionable operations.
To access this resource, please make sure to accept cookies.